Compare Nasdaq Inc (NDAQ) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nasdaq Inc vs Sana Biotechnology Inc — how do they compare? Nasdaq Inc trades at $94.7 (market cap $53.13B), while Sana Biotechnology Inc trades at $3.17 (market cap $1.03B). The key difference: Nasdaq Inc is far larger — about 51.6× Sana Biotechnology Inc's market cap, and Nasdaq Inc pays a 1.22% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| NDAQ | SANA | |
|---|---|---|
Market Cap | $53.13B | $1.03B |
Sector | Financials | Health |
52-Week High | $100.98 | $5.92 |
52-Week Low | $76.85 | $2.68 |
Enterprise Value | $59.58B | $946.04M |
Dividend Yield | 1.22% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nasdaq (NDAQ) trades at $95.04, down 1.9% on the day, with a bullish technical signal from moving averages but bearish oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.07 exceeding the $0.984 estimate. Revenue grew to $8.26B in 2025, and net income margin improved to 22.52%. Recent news highlights strategic acquisitions like Dasseti to enhance AI capabilities.
The outlook is positive with a consensus price target of $109.20, implying 15% upside. Key opportunities include continued earnings growth and expansion in data-driven investment technology. Risks involve market volatility and execution of acquisition integration. Analyst sentiment is bullish with 61% buy ratings.
SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.
Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
